language_icon
EN
HI

Metropolis Healthcare Share price

METROPOLIS

468.1

11.20 (2.45%)
NSE
BSE
Last updated on 10 Apr, 2026 | 15:40 IST
Today's High

471.80

Today's Low

455.70

52 Week Low

374.44

52 Week High

565.75

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Metropolis Healthcare Chart

Metropolis Healthcare Share Key Metrics

Volume
1.53 L
Market Cap
9705.01 CR
LTQ@LTP
5@468.10
ATP
465.46
Var Margin
14.1 %
Circuit Range
365.55-548.25
Delivery %
34.91 %
Value
7.12 CR
ASM/GSM
No
Market Lot
1

Summary

At 10 Apr, 2026 | 15:40, Metropolis Healthcare share price stands at ₹468.1, showing a 11.20% 2.45 for the day. The stock’s intraday movement has stayed between ₹455.70 and ₹471.80, while on a 52-week basis it has fluctuated from ₹374.44 to ₹565.75.
In terms of trading activity, Metropolis Healthcare has recorded a volume of 153063 shares, with a market capitalisation of ₹207327768. The stock’s Average Traded Price (ATP) stands at ₹46546, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 5,46810. The stock operates within a circuit range of ₹365.55-548.25, with a Value of ₹7.12 CR. The Delivery Percentage for the day is 34.91%. Additionally, Metropolis Healthcare currently falls under the No framework, and trades with a market lot size of 1.

Metropolis Healthcare Fundamentals

View More
P/E Ratio

56.39

P/B Ratio

6.3

Div. Yield

0

Sector P/E

50.98

Sector P/B

-16.44

Sec. Div. Yield

2.37

Metropolis Healthcare Resistance and Support

Pivot 454.7

Resistance

First Resistance

461.9

Second Resistance

466.9

Third Resistance

474.1

Support

First Support

449.7

Second Support

442.5

Third Support

437.5

Metropolis Healthcare Futures & Options

Data Not Found

Metropolis Healthcare Shareholding Pattern

View More
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
Total Promoters
Segment
Percent

Total Promoters

48.88%

Mutual Fund

32.22%

Insurance

2.16%

Foreign Institutional Investors

11.68%

Domestic Institutional Investors

0.36%

Retail

4.71%

Others

-0.01%

Total Promoters
MAR '25
48.89%
JUN '25
48.89%
SEP '25
48.89%
DEC '25
48.88%

Metropolis Healthcare Corporate Actions

DateAgenda
2026-02-04Quarterly Results & Bonus issue
2025-11-04Quarterly Results & Interim Dividend
2025-08-07Quarterly Results
2025-05-13Audited Results
2025-02-04Quarterly Results

Metropolis Healthcare News

Metropolis Healthcare Limited

Metropolis Healthcare reports ~23% YoY consolidated revenue growth for Q4 FY26. This growth is driven by a ~30% increase in B2B revenue and strong performance in the TruHealth wellness and specialty testing segments.
Apr 03 2026 13:04:00

Metropolis Healthcare Limited

Metropolis Healthcare allotted 155,495,826 bonus equity shares on March 23, 2026, in a 3:1 ratio. This increased the total number of paid-up shares from 51,831,942 to 207,327,768, and the paid-up share capital from ₹10.37 crore to ₹41.47 crore.
Mar 23 2026 20:03:00
Read More

About Metropolis Healthcare

NSE : 9581  
BSE : 542650  
ISIN : INE112L01020  

Dr. Sushil Kanubhai Shah one of The Promoters commenced pathology business in January 1980 as a partnership firm in the name of Dr. V. K. Desai’s Hospital having Dr. Kanubhai M. Shah Dr. Sushil Kanubhai Shah and Dr. Vasant Kalyandas Desai as partners. The partnership was continued by Dr. Sushil Kanubhai Shah Dr. Kanubhai M. Shah and Dr. Duru Sushil Shah from September 30 1981 onwards. In June 1989 upon death of Dr. Kanubhai M. Shah the partnership was continued by Dr. Sushil Kanubhai Shah and Dr. Duru Sushil Shah. Prior to March 18 1995 Dr. Sushil Kanubhai Shah was also carrying on a business of radioimmunoassay and pathology laboratory on a sole proprietorship basis. On March 20 1995 the said sole proprietorship business was converted into a partnership with Dr. Sushil Kanubhai Shah Dr. Duru Sushil Shah and Aparna S. Shah (Rajadhyaksha) as partners in the name and style of Metropolis Lab. In January 1998 Ameera Sushil Shah was inducted as an additional partner in Metropolis Lab. With effect from February 1 2002 the business of Metropolis Lab was transferred to Dr. V. K. Desai’s Hospital as a going concern. In May 2002 Dr. G. S. K. Velu and Subbulakshmi K. Velu were admitted as partners in Dr. V. K. Desai Hospitals. The name of Dr. V. K. Desai’s Hospital was changed to Metropolis Health Services in November 2002. Further in April 2003 Ameera Sushil Shah Jaswanti Kanubhai Shah Sadacharan Gomanthybabu and Gomathybabu Gomathy were admitted as partners in Metropolis Health Services.In July 2003 Metropolis Health Services was converted into a private limited company as Metropolis Health Services (India) Private Limited (“MHSIPL”) under the Companies Act 1956. The name of MHSIPL was changed to Metropolis Health Services (India) Limited (“MHSIL”) pursuant to a ‘Fresh Certificate of Incorporation Consequent upon Change of Name on Conversion to Public Limited Company’ granted by RoC on March 1 2006. In January 2009 MHSIL amalgamated with Pathnet India Private Limited which was a wholly owned subsidiary of MHSIL. For details see “– Scheme of amalgamation between Pathnet India Private Limited and Metropolis Health Services (India) Limited Metro Home Health Services Private Limited Lister Metropolis Laboratory and Research Centre Private Limited Tripoli Path Lab Private Limited and Diwanchand Metropolis Diagnostics Services Private Limited”.Pathnet India Private Limited was incorporated at New Delhi as a private limited company under the Companies Act 1956 pursuant to the ‘Certificate of Incorporation’ granted by the Registrar of Companies N. C. T. of Delhi and Haryana on November 10 2000. The name of The Company was changed to Pathnet India Limited pursuant to a ‘Fresh Certificate of Incorporation Consequent upon Change of Name on Conversion to Public Limited Company’ granted by RoC on July 1 2009. The name of The Company was changed to Metropolis Healthcare Limited pursuant to a ‘Fresh Certificate of Incorporation Consequent upon Change of Name’ granted by RoC on September 23 2009. Major events and milestones of The Company :2002-First major acquisition by the Company of Sudharma2004-The Company was accredited by National Accreditation Board for Testing and Calibration Laboratories (Department of Science & Technology India)2005-The Company received accreditation from The College of American Pathologists2006-Investment by The Western India Trustee and Executor Company in the Company-Acquisition of M/s. Lister Laboratory and Research Centre Private Limited in Chennai2007-Acquisition of Desai Clinical Laboratory in Surat2008-Acquisition of R.V Diagnostics & Healthcare Center Private Limited in Bangalore2009-Scheme of Amalgamation 20092010-Investment by Foxcreek Investment Limited in the Company2011-Acquisition of LabOne in Raipur2012-Acquisition of Micron Laboratories in Mumbai-Acquisition of subsidiary in Kenya-Acquisition of Dr. Patel Pathology Laboratory Private Limited in Nashik-Incorporation of subsidiary in Mauritius2013-Acquisition of M/s. Ekopath Center-Pathology and Cytology Division in Guwahati-Establishment of GRL in Mumbai2014-Acquisition of subsidiary in Ghana2015-Investment by CA Lotus Investments in the Company-Incorporation of subsidiary in Uganda-Incorporation of branch office in Zambia2017-Acquisition of Sanjeevani Pathology Laboratory in Rajkot2018-Public-Private partnership agreement executed with National AIDS Control Organisation Government of India-Scheme of Amalgamation 2018-Incorporation of subsidiary in Tanzania  Awards achievements and certifications :2010-The Company was awarded the “Diagnostic Services Company of the Year” by Frost & Sullivan2012-The Company was felicitated for providing “Outstanding Quality Diagnostic Services” by HIV Congress 20122014-The Company was awarded the “Most Promising Brand” by the World Consulting and Research Corporation-The Company was awarded as a “Quality Brand” by Quality Brands India2015-The Company was awarded the “Best Diagnostic Company of the Year” at the National Awards for Excellence in Healthcare 2015-The Company was awarded the “Diagnostic Services Company of the Year” by the VCCircle Network-The Company was awarded for “Excellence in Productive Employment Creation” by Business Today2018-The Company was awarded for “Best in Health and Fitness” in the Digital Campaign Awards by LH Insights-The Company was awarded for “Excellence in Customer Service & Delivery” by Biotrains-The Company was awarded special jury mention for “Service Excellence (Diagnostic Centre)” by FICCI at the Healthcare Excellence Awards2018-2019-The Company was awarded “Iconic Pathology Lab Mumbai” by Midday Health & Wellness Icons

Read More

Metropolis Healthcare Management

NamePosition
Mrs. Ameera Sushil Shah Exe.Chairman & W T D
Mr. Hemant Sachdev Non Exe.Non Ind.Director
View More

Metropolis Healthcare FAQs

The Buying Price of Metropolis Healthcare share is 468.1 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Metropolis Healthcare stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Metropolis Healthcare, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Metropolis Healthcare shares is 56.39. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Metropolis Healthcare shares is 6.3. Useful to assess the stock's value relative to its book value.

To assess Metropolis Healthcare’s valuation compare Sector P/E, P/B which are 50.98 & -16.44 with sector averages, along with growth rates and financial metrics.

The Market Cap of Metropolis Healthcare is 9705.01 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Metropolis Healthcare share price is 565.75 & 374.44. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Metropolis Healthcare belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost